Format

Send to

Choose Destination
Curr Opin Oncol. 2001 May;13(3):154-9.

Treatment controversies in medulloblastoma.

Author information

1
Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA.

Erratum in

  • Curr Opin Oncol 2001 Sep;13(5):413.

Abstract

Medulloblastoma, the most common primary malignant brain tumor in children, is a radiosensitive and chemosensitive tumor. Nevertheless, medulloblastoma remains a management challenge for the clinical oncologist, because the optimal sequence and dosage for each treatment modality has not yet been defined. In addition, effective management strategies for medulloblastoma may result in profound neuroendocrine and neuropsychologic sequelae. In this article, we review the clinical and biologic prognostic factors for classifying medulloblastoma, current strategies for the management of this disease, and potential strategies to prevent or minimize long-term treatment sequelae.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center